Quest Diagnostics Inc Finance Lease, Right-of-Use Asset, Amortization
Quest Diagnostics Inc (DGX) reported Finance Lease, Right-of-Use Asset, Amortization of $3.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-02-26
- Quest Diagnostics Inc finance lease, right-of-use asset, amortization for the quarter ending 2019-12-31 was $2.00M.
- Quest Diagnostics Inc finance lease, right-of-use asset, amortization for the quarter ending 2019-09-30 was $1.00M.
- Quest Diagnostics Inc finance lease, right-of-use asset, amortization for the quarter ending 2019-06-30 was $2.00M.
- Quest Diagnostics Inc finance lease, right-of-use asset, amortization for the quarter ending 2019-03-31 was $2.00M.
- Quest Diagnostics Inc finance lease, right-of-use asset, amortization for fiscal 2025 was $3.00M, a 200.00% increase from fiscal 2024.
- Quest Diagnostics Inc finance lease, right-of-use asset, amortization for fiscal 2024 was $1.00M, a 50.00% decline from fiscal 2023.
- Quest Diagnostics Inc finance lease, right-of-use asset, amortization for fiscal 2023 was $2.00M, a 0.00% change from fiscal 2022.
- Quest Diagnostics Inc finance lease, right-of-use asset, amortization for fiscal 2022 was $2.00M, a 0.00% change from fiscal 2021.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.00M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $1.00M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $2.00M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $2.00M 10-K · filed 2025-02-20 | |||
| 2021-12-31 | $2.00M 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $6.00M 10-K · filed 2023-02-21 | |||
| 2019-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.00M derived: sum of 2 quarters · filed 2022-02-28 | $5.00M derived: sum of 3 quarters · filed 2022-02-28 | $7.00M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.00M 10-Q · filed 2019-10-23 | $3.00M derived: sum of 2 quarters · filed 2019-10-23 | $5.00M 10-Q · filed 2019-10-23 | |
| 2019-06-30 | $2.00M 10-Q · filed 2019-07-24 | $4.00M 10-Q · filed 2019-07-24 | ||
| 2019-03-31 | $2.00M 10-Q · filed 2019-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |